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Abstract: The transient receptor potential melastatin-subfamily member 7 (TRPM7) is a ubiquitously
expressed chanzyme that possesses an ion channel permeable to the divalent cations Mg2+, Ca2+,
and Zn2+, and an α-kinase that phosphorylates downstream substrates. TRPM7 and its homologue
TRPM6 have been implicated in a variety of cellular functions and is critically associated with
intracellular signaling, including receptor tyrosine kinase (RTK)-mediated pathways. Emerging
evidence indicates that growth factors, such as EGF and VEGF, signal through their RTKs, which
regulate activity of TRPM6 and TRPM7. TRPM6 is primarily an epithelial-associated channel, while
TRPM7 is more ubiquitous. In this review we focus on TRPM7 and its association with growth factors,
RTKs, and downstream kinase signaling. We also highlight how interplay between TRPM7, Mg2+
and signaling kinases influences cell function in physiological and pathological conditions, such as
cancer and preeclampsia.
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1. Introduction
The transient receptor potential melastatin 7 (TRPM7) and its close homologue TRPM6 share the
unique feature of a cation channel fused to a C-terminal α-kinase domain [1–3]. TRPM6 and TRPM7
are present in a tetrameric form and each subunit comprises six transmembrane segments (S1-6), and a
channel pore permeable to Mg2+, Ca2+, and Zn2+, located between segments 5 and 6 (Figure 1) [4,5].
TRPM7 is ubiquitously expressed, whereas TRPM6 is mostly expressed in cells from kidneys and
intestines. In spite of their similarities, they are not compensated by each other, indicating that they are
not redundant. TRPM7 was initially proposed to regulate, and itself to be regulated by, intracellular
Mg2+ levels, with Mg-ATP below 1mM strongly activating the channel [6]. The importance of TRPM7
in cellular Mg2+ homeostasis has been investigated in several cell types, including leukocytes, platelets,
vascular smooth muscle cells (VSMCs), cardiomyocytes, cardiac fibroblasts, osteoblasts, and tumor cells,
in both physiological and pathological conditions [6–13]. Experiments using TRPM7 overexpressing
cells demonstrated important mechanisms underlying the role of TRPM7 in Mg2+ homeostasis, and this
was confirmed in the recently described crystal structure of mouse TRPM7, where partially hydrated
Mg2+ ions occupy the center of the conduction pore [3]. However, the importance of TRPM7 in Mg2+
homeostasis has also been questioned by some studies, since the deletion of TRPM7 in T cells did not
affect acute uptake or the maintenance of total cellular Mg2+ [14]. However, this may relate to the cell
type studied, because Mg2+ is typically regulated by MagT1 in immune cells.
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Figure 1. Schematic structure of the TRPM7 channel and kinase. The general structure of the TRPM7 
has four Melastatin Homologous Regions (MHR) in the N-terminal domain, and six transmembrane 
segments (aa 756–1095). The pore (aa 1039–1056) is located between the S5 and S6. The C terminal 
domain contains the transient receptor potential (TRP) region (aa 1109–1128), common to TRP family 
members, followed by the coiled coil (CC) domain connecting loop (aa 1198–1250); Serine- and 
threonine-rich domains (aa 1380–1596), and the α-kinase domain (aa 1597–1821). 
TRPM6 and TRPM7 have been linked to many signaling pathways. Emerging evidence indicates 
an important role for these systems in growth factor signaling through receptor tyrosine kinases 
(RTK). The C-terminal α-kinase domain induces phosphorylation of many downstream targets 
involved in RTK signaling including annexin A1, calpain II, myosin II, PLCγ2, Src, and SMAD2 [15], 
and regulates epigenetic modifications [16]. TRPM7 kinase domain may also influence TRPM7 
channel function, although the exact mechanisms remain unclear [17–19].  
In addition to controlling Mg2+ transport across cell membranes, TRPM7, together with other 
Ca2+ channels, regulates Ca2+ influx in many cell types [20,21]. In angiotensin II (Ang II)-stimulated 
cardiac fibroblasts, TRPM7 is functionally active and controls both Mg2+ and Ca2+ influx [9]. In 
neuroblastoma cells, bradykinin-induced activation of TRPM7 mediates Ca2+ influx in a kinase-
independent manner [22] and Ca2+ entry in macrophages triggered by lipopolysaccharide (LPS) is 
controlled by TRPM7, as observed in a cell-specific deletion model using a Cre/Lox system [23]. The 
kinase domain of TRPM7 also plays an important role in Ca2+ homeostasis by modulating store-
operated calcium channels (SOCE) [24,25].  
TRPM7 is also permeable to Zn2+ and may be an important regulator of cellular Zn2+ dynamics. 
This was originally identified in mouse cortical neurons, where activation of TRPM7 channels 
increased intracellular Zn2+, and TRPM7 knockdown using a short hairpin RNA reduced TRPM7-like 
current and intracellular Zn2+ concentration [26]. Additionally, a recent study showed that TRPM7 is 
an intracellular Zn2+ storage vesicle, which sequesters Zn2+ during cytosolic overload, and releases 
Zn2+ under oxidizing conditions [27]. Interestingly, other channels from the TRPM family are also 
permeable to Zn2+, such as TRPM2, TRPM3, and TRPM5 [28–30]. 
Receptor tyrosine kinases (RTKs), through which growth factors signal, are membrane-
associated receptors [31]. Upon growth factor binding, autophosphorylation of RTKs induces 
phosphorylation and activation of intracellular non-receptor tyrosine kinases that influence 
phosphorylation of downstream target proteins. The activation of RTKs is involved in critical 
signaling pathways and cell functions, including proliferation, differentiation, migration and 
contraction, processes also dependent on Mg2+ and Ca2+. The RTK family comprises major growth 
factor receptors, such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor 
receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), nerve growth factor receptor 
(NGFR), fibroblast growth factor receptor (FGFR), and insulin-like growth factor receptor (IGFR) [32]. 
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TRPM6 and TRPM7 have been linked to many signaling pathways. Emerging evidence indicates
an important role for these systems in growth factor signaling through receptor tyrosine kinases (RTK).
The C-terminal α-kinase domain induces phosphorylation of many downstream targets involved in
RTK signaling including annexin A1, calpain II, myosin II, PLCγ2, Src, and SMAD2 [15], and regulates
epigenetic modifications [16]. TRPM7 kinase domain may also influence TRPM7 channel function,
although the exact mechanisms remain unclear [17–19].
In addition to controlling Mg2+ transport across cell membranes, TRPM7, together with other Ca2+
channels, regulates Ca2+ influx in many cell types [20,21]. In angiotensin II (Ang II)-stimulated cardiac
fibroblasts, TRPM7 is functionally active and controls both Mg2+ and Ca2+ influx [9]. In neuroblastoma
cells, bradykinin-induced activation of TRPM7 mediates Ca2+ influx in a kinase-independent
manner [22] and Ca2+ entry in macrophages triggered by lipopolysaccharide (LPS) is controlled
by TRPM7, as observed in a cell-specific deletion model using a Cre/Lox system [23]. The kinase
domain of TRPM7 also plays an important role in Ca2+ homeostasis by modulating store-operated
calcium channels (SOCE) [24,25].
TRPM7 is also permeable to Zn2+ and may be an important regulator of cellular Zn2+ dynamics.
This was originally identified in mouse cortical neurons, where activation of TRPM7 channels increased
intracellular Zn2+, and TRPM7 knockdown using a short hairpin RNA reduced TRPM7-like current
and intracellular Zn2+ concentration [26]. Additionally, a recent study showed that TRPM7 is an
intracellular Zn2+ storage vesicle, which sequesters Zn2+ during cytosolic overload, and releases Zn2+
under oxidizing conditions [27]. Interestingly, other channels from the TRPM family are also permeable
to Zn2+, such as TRPM2, TRPM3, and TRPM5 [28–30].
Receptor tyrosine kinases (RTKs), through which growth factors signal, are membrane-associated
receptors [31]. Upon growth factor binding, autophosphorylation of RTKs induces phosphorylation and
activation of intracellular non-receptor tyrosine kinases that influence phosphorylation of downstream
target proteins. The activation of RTKs is involved in critical signaling pathways and cell functions,
including proliferation, differentiation, migration and contraction, processes also dependent on Mg2+
and Ca2+. The RTK family comprises major growth factor receptors, such as epidermal growth factor
receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor
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receptor (PDGFR), nerve growth factor receptor (NGFR), fibroblast growth factor receptor (FGFR), and
insulin-like growth factor receptor (IGFR) [32].
In 2009, Bindels and colleagues demonstrated that EGF activates EGFR signaling and promotes
TRPM6 translocation from the cytosol to the membrane in kidney cells, through Src family
tyrosine kinases [33]. These effects were abolished by the monoclonal antibody specific to EGFR
(cetuximab) [33,34]. Similar effects were observed in mice treated with erlotinib [35] and in mammary
epithelial cells treated with tyrphostin AG1478, inhibitors of EGFR tyrosine kinase [36]. These studies
were amongst the first to show a relationship between TRPM6, Mg2+ and growth factors and might
explain the severe hypomagnesemia observed as a side effect in cancer patients treated with EGFR
inhibitors [37]. Most clinical trials reported electrolyte disorders, particularly hypomagnesemia and
hypocalcemia, in cancer patients treated with EGFR inhibitors [34]. Whether EGFR inhibitors also
influence TRPM7 in cancer patients is unclear.
2. Transient Receptor Potential Melastatin 7 Cation Channel (TRPM7)
2.1. Characteristics and Regulation of TRPM7
Among the more than 300 mammalian ion channels, only TRPM7 and TRPM6 have a C-terminal
kinase, which belongs to a specific subfamily of atypical protein kinases (APKs), known as α-kinases,
displaying little amino acid sequence similarity to conventional protein kinases [3,38,39]. To date very
few α-kinases have been identified. Those that have been described include eukaryotic Elongation
Factor 2 Kinase (eEF2K), alpha-kinase 1 (lymphocyte alpha-kinase, LAK or ALPK1), alpha-kinase 2
(heart alpha-kinase, HAK or ALPK2) and alpha-kinase 3 (muscle alpha-kinase, MAK or ALPK3), TRPM6
and TRPM7 [38]. The crystal structure of TRPM7 shows that the N-terminal central catalytic core is
structurally similar to the classical protein kinase, whereas the structure of the C-terminal lobe resembles
metabolic enzymes with ATP-grasp folds [3,39]. The TRPM7 α-kinase predominantly phosphorylates
serine/threonine residues onα-helices. Since the cytoplasmic domain is rich in serine/threonine residues,
activation of TRPM7 can induce autophosphorylation as well as phosphorylation of downstream targets
(Figure 1) [40,41]. TRPM7-kinase phosphorylates annexin-A1 (Ser5) [42]; myosin IIA (Thr1800, Ser1803
and Ser1808) [43]; eukaryotic elongation factor 2 cognate kinase (eEF2-K) (Ser77) under low Mg2+
concentrations [44]; SMAD2 (Ser465/467) [15]; and phospholipase Cγ2 (PLCγ2) (Ser1164) [45]. TRPM7
is cleaved by caspases at Asp1510, dissociating the kinase from the conducting pore, with the cleaved
channel exhibiting enhanced activity, and the kinase domain retaining phosphotransferase activity [46].
TRPM7 cleaved fragments translocate and accumulate in the nucleus, where they phosphorylate
specific serines and threonines on histones, affecting gene expression. It seems that different cleaved
fragments are expressed in different tissues, implying a distinct role for TRPM7 cleaved fragments in a
tissue-specific manner [16]. A similar phenomenon has been described for TRPM6 kinase [47].
2.2. Interactions between TRPM7 Kinase and TRPM7 Channel Domains
Despite intense investigations, there are still controversies regarding the functional significance
of the coupling between the α-kinase and the channel domain of TRPM7. Mutations at specific sites
that disrupt kinase activity do not affect TRPM7 channel activity and sensitivity to inhibition by
divalent cations (Figure 2). In addition, there were no significant differences in channel activity and
Ca2+ influx between wild type and TRPM7 kinase mutant cells [48]. These data were confirmed in
in vivo experiments, where TRPM7 kinase-dead mutant mice have normal serum Mg2+ levels and
normal development [15,19,48]. However, many studies support a link between TRPM7 channel and
its C-terminal kinase. In HEK293 cells overexpressing mutant human TRPM7 K1648R and G1799D,
activity of the kinase domain and function of the channel domain are altered by changes in sensitivity
to intracellular Mg2+ [49]. Interplay between the kinase and channel is supported by studies showing
that: (i) cleavage of TRPM7 kinase is associated with increased cation channel activity [46], (ii) Mg2+
nucleotide modulation of TRPM7 channel through the kinase domain [50,51], and (iii) regulation of
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TRPM7 by cAMP/PKA, which requires a functional kinase domain [52]. Additionally, an in vivo model
carrying a truncated kinase domain showed reduced intracellular Mg2+, hypomagnesemia [17] and
increased sensitivity to Ca2+ in mast cells [53]. Therefore, it seems that the catalytic activity of the
kinase is not essential for channel gating, but somehow it modulates and “fine tunes” channel activity
and sensitivity to Mg2+ nucleotides.
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Figure 2. Schematic overview of TRPM7 mutations. Mutations that have been identified are 
highlighted. Numbers indicate the single amino acids or regions that affect TRPM7 channel or kinase 
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In the plasma membrane, TRPM7 functions as a homodimer, but in some conditions it also 
heterodimerizes with TRPM6. In some cell-based systems, TRPM6 seems to require TRPM7 for full 
activation and in the complexed state has been termed TRPM6/TRPM7 [60]. The crucial role of 
TRPM7 in the complex formation was demonstrated in molecular studies, where TRPM6 deficiency 
in trophoblast stem cells results in a reduction in TRPM6/7 currents, while deficiency in TRPM7 
completely abolished the TRPM6/7 currents [53]. TRPM6 and TRPM7 possess several 
phosphorylation sites and can be phosphorylated independently of autophosphorylation, TRPM7 
can also be transphosphorylated by TRPM6 (Figure 3) [61]. This cross activation was demonstrated 
in co-transfection experiments, which showed that TRPM6 expression was able to 
transphosphorylate serine and threonine motifs in TRPM7-K1646R kinase dead mutant. 
Transphosphorylation of TRPM6 by TRPM7 is very weak. These phosphorylated residues are present 
in the N-terminal, channel, and C terminus, including the kinase domain of the TRPM7-K1646R [61). 
These phenomena have been demonstrated in cell models but the (patho) physiological significance 
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Figure 2. Schematic overview of TRPM7 mutations. Mutations that have been identified are highlighted.
Numbers indicate the single amino acids or regions that affect TRPM7 channel or kinase activity [17,19,
46,48,49,54–59].
2.3. Relationship between TRPM6 and TRPM7
In the plasma membrane, TRPM7 functions as a homodimer, but in some conditions it also
heterodimerizes with TRPM6. In so e cell-based systems, TRPM6 seems to require TRPM7 for
full activation and in the complexed state has been ter ed P 6/ P 7 [60]. The crucial role of
TRPM7 in the complex formation was demonstrated in molecular studies, where TRPM6 deficiency in
trophoblast stem cells results in a reduction in TRPM6/7 currents, while deficiency in TRPM7 completely
abolished the TRPM6/7 currents [53]. TRPM6 and TRPM7 possess several phosphorylation sites and can
be phosphorylated independently of auto hosphorylation, TRPM7 can also be transphosphorylated
by TRPM6 (Figure 3) [61]. This cross activation was demonstrated in co-transfection experiments,
which showed that TRPM6 expression was able to transp osphorylate serine and threonine motifs
in TRPM7-K1646R kinase dead mutant. Transphosphorylation of TRPM6 by TRPM7 is very weak.
These phosphorylated residues are present in the N-terminal, channel, and C terminus, including the
ki ase domain of the TRPM7-K1646R [61]. These phe omena have been demonstrated in cell models
but the ( atho) physiological significance in vivo remains to be determined. TRPM7 seems to interact
with other Mg2+ channels. In DT40 B cells and colon carcinoma cells, TRP 7 deficie cy was associated
with increased expression of MagT1 [62–64].
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Figure 3. Transphosphorylation of TRPM7 by TRPM6. TRPM6 is able to induce phosphorylation of 
TRPM7 in the indicated residues. Red stars indicate the location of the residues. Residues in blue are 
also residues of autophosphorylation. 
2.4. TRPM7 and Cell Function  
The indispensable role of TRPM7 in cellular biology is likely linked to its important role in the 
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structural cofactors of numerous enzymes and are major regulators of signaling molecules, DNA 
stability, cell cycle and transcription factors [65,66]. Deficiency of Mg2+ and Zn2+ suppress cell cycle 
progression leading to growth failure [67,68]. Mg2+ supplementation and overexpression of Mg2+ 
transporters rescued growth impairment caused by TRPM7 deficiency [17,62]. Ca2+, which is also 
influenced by TRPM7, is critically involved in controlling cell function including cell proliferation, 
contraction, secretion, migration and differentiation [69–71]. Associated with many of the Ca2+- and 
Mg2+- regulated signaling pathways is the activation of tyrosine kinases [35,72–75]. In vascular cells, 
TRPM7 appears to be the most important cation channel involved in controlling [Mg2+]i. TRPM7 is 
regulated by vasoactive factors, such as AngII, aldosterone, endothelin-1 and bradykinin [76–80]. 
Ang II regulates vascular TRPM7 acutely by inducing phosphorylation and chronically by increasing 
expression at the mRNA and protein levels [76,79]. Also, siRNA downregulation of vascular TRPM7 
caused a reduction in [Mg2+]i and attenuated Ang II-mediated VSMC growth [7]. VSMCs from 
hypertensive rats exhibit reduced TRPM7 expression and decreased TRPM7 activation, as assessed 
by translocation of annexin-1 (TRPM7 kinase target) to the membrane [79]. Findings from cell-based 
studies and animal models indicate that TRPM7 activation and increased Mg2+ influx are 
vasoprotective as they protect against vascular calcification, oxidative stress and fibrosis [81].  
3. Receptor Tyrosine Kinase Signaling and Mg2+  
3.1. Characteristics and Regulation of Receptor Tyrosine Kinases  
Protein kinases induce phosphorylation by catalyzing the transfer of phosphate from adenosine 
triphosphate (ATP) to serine, threonine and tyrosine residues on protein substrates and are key 
enzymes in the regulation of intracellular signaling pathways [82,83]. These ATP- and phosphate-
dependent processes have an obligatory requirement for Mg2+. Data from the human genome 
revealed that of the proteins phosphorylated on tyrosine residues, 58 are receptor tyrosine kinases 
Figure 3. Transphosphorylation of TRPM7 by TRPM6. TRPM6 is able to induce phosphorylation of
TRPM7 in the indicated residues. Red stars indicate the location of the residues. Residues in blue are
also residues of autophosphorylation.
2.4. TRPM7 and Cell Function
The indispensable role of TRPM7 in cellular biology is likely linked to its important role in the
regulation of homeostasis of divalent cations Mg2+, Zn2+, and Ca2+. Mg2+ and Zn2+ are catalytic
and structural c factors of numerous enzyme and are major regulators of signaling molecules, DNA
ability, cell cycle and transc iption factor [65,66]. Deficiency of Mg2+ and Zn2+ suppr ss cell cycle
progression leading to g owth fa lure [67,68]. Mg2+ supplementation and overexpression of Mg2+
transporters r scued growth imp irm nt caused by TRPM7 deficiency [17,62]. Ca2+, which is also
influenced by TRPM7, is critically nvolved in controlling cell function including cell proliferation,
contraction, secretion, migra on and differentiation [69–71]. Associated with many of the Ca2+- and
Mg2+- regulat d signaling pathw ys is th activation of tyrosine kin s s [35,72–75]. In vascul r cells,
TRPM7 appears to be the most important cation channel involved in controlling [Mg2+]i. TRPM7
is regulated by vasoactiv factors, such as AngII, aldost ro e, endotheli -1 and bradykinin [76–80].
Ang II regulates vas ular TRPM7 acutely by inducing phosphorylation a d chronic ll by creasing
expression at he mRNA and protein l vels [76,79]. Also, siRNA dow regulation of vascular TRPM7
caus d a reduction in [Mg2+]i and attenuated Ang II-mediated VSMC growth [7]. VSMCs from
hypertensive rats exhibit reduced TRPM7 expression and ecr ased TRPM7 activation, as as essed
b translocation of annexin-1 (TRPM7 kinase target) to the membrane [79]. Findings from cell-ba
studies and nimal mod ls indicate that TRPM7 ctivati n and increased Mg2+ influx are vasoprotective
as they protect against vascular calcification, oxidative stress and fibrosis [81].
3. Receptor Tyrosine Kinase Signaling and Mg2+
3.1. Characteristics and Regulation of Receptor Tyrosine Kinases
Protein kinases induce phosphorylation by catalyzing the transfer of phosphate from adenosine
triphosphate (ATP) to serine, threonine and tyrosine residues on protein substrates and are key enzymes
in the regulation of intracellular signaling pathways [82,83]. These ATP- and phosphate-dependent
processes have an obligatory requirement for Mg2+. Data from the human genome revealed that
of the proteins phosphorylated on tyrosine residues, ≈58 are receptor tyrosine kinases and ≈32 are
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non-receptor tyrosine kinases [32,84]. All RTKs have a similar molecular architecture, comprising three
major domains, including an extracellular ligand-binding domain, an intracellular tyrosine kinase
domain and a transmembrane domain [31]. RTKs are typically activated by growth factors [85–88].
Magnesium is a crucial divalent cation required for the activity of protein kinases, including RTKs
(VEGFR, EGFR, FGFR, PDGFR) and non-receptor tyrosine kinases (Src, Abl, Jak, FAK, SOCS) [89].
In cell-based studies, high Mg2+ concentration causes increased tyrosine kinase activity. Data obtained
with crystallography experiments revealed that two Mg2+ molecules are required for enzyme activity
and phosphoryl transfer: one bound to ATP (Mg-ATP) situated between the small and large lobes
of the kinase domain, bound to β and γ-phosphates and to the aspartate of the DFG (Asp-Phe-Gly),
which are the first residues to be activated in protein kinases; and in high [Mg2+]i conditions, another
Mg2+ binds to α and γ-phosphates and to the asparagine amide nitrogen within the catalytic loop [90].
The importance of Mg2+ in the regulation of kinase activity occurs in four steps: (i) Mg-ATP binds to
the enzyme; (ii) the kinase binds to the protein substrate and catalyzes the transfer of the phosphoryl
group; (iii) phosphorylated protein and Mg2+ are released; and (iv) Mg2+-ADP is released and the
catalytic cycle is completed [91] (Figure 4).
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(1) Mg-ATP is the first to bind to the enzyme followed by Mg2+; (2) the kinase binds to the protein 
substrate and catalyzes the transfer the phosphoryl group; (3) phosphorylated protein and Mg2+ are 
released; and (4) Mg-ADP is released and the catalytic cycle is finalized. 
3.2. Growth Factors and Receptor Tyrosine Kinase Signaling 
Following binding of growth factors to their specific RTKs, cytoplasmic proteins containing Src 
homology region 2 (SH2) or phosphotyrosine-binding (PTB) domains are recruited to the cell 
membrane. These recruited proteins either have intrinsic enzymatic activity, such as Src and PLCγ, 
or serve as docking proteins that function as “assembly platforms” and recruit additional enzymes 
[32,75,85,92]. Activated RTKs are able to trigger a wide range of downstream signaling pathways, 
including RAS/RAF/MEK/MAPK, PLCγ/PKC, PI3K/AKT/mTOR, and JAK/STAT (Figure 5) [93]. 
Activated RTKs bind to the adaptive protein growth factor receptor-bound 2(Grb2) and recruit 
Son of Sevenless homolog protein (SOS), which interacts with its downstream target Ras, a small GTP 
binding protein, and transforms it to the active conformation by exchanging GDP for GTP [94]. Ras 
recruits the serine/threonine protein kinase, Raf, to the membrane, where it becomes activated by 
Figure 4. Importance of Mg2+ for the kinase catalytic activity. Two Mg2+ molecules are required for
enzymatic activity and phosphoryl transfer: one bound to ATP (Mg-ATP) situated between the small
(N-lobe) and large lobe (C-Lobe) of the kinase domain, and another Mg2+ situated in the catalytic loop.
(1) Mg-ATP is the first to bind to the enzyme followed by Mg2+; (2) the kinase binds to the protein
substrate and catalyzes the transfer the phosphoryl group; (3) phosphorylated protein and Mg2+ are
released; and (4) Mg-ADP is released and the catalytic cycle is finalized.
3.2. Growth Factors and Receptor Tyrosine Kinase Signaling
Following binding of growth factors to their specific RTKs, cytoplasmic proteins containing Src
homol gy region 2 (SH2) or phosphotyr sine-binding (PTB) domains are recruited to the ell membrane.
These recruited proteins either have intrinsic enzymatic activity, such as Src and PLCγ, or serve as
docking protein that f nction as “a sembly platforms” and recruit additional enzymes [32,75,85,92].
Activat d RTKs are able to rigger a wide rang of downstream signaling p thways, including
RAS/RAF/MEK/MAPK, PLCγ/PKC, PI3K/AKT/mTOR, and JAK/STAT (Figure 5) [93].
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The phosphoinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling 
pathway is also initiated by binding of growth factors to RTKs. Activated RTKs recruit the PI3K to 
the plasma membrane where the PI3K subunit p110 catalyzes phosphorylation of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3 
then provides docking sites for signaling proteins, including AKT and 3-phosphoinositide-
dependent kinase 1 (PDK1) [97,98]. Activated AKT phosphorylates many other downstream proteins, 
such as glycogen synthase kinase 3 (GSK3), the forkhead family of transcription factors (FOXOs) and 
mTOR. Multiple components of the PI3K/AKT/mTOR pathway activated by RKTs play a pivotal role 
in the regulation of cell growth, proliferation and differentiation [93,98–100]. 
Another signaling system linked to RTKs is PLCγ/protein kinase C (PKC). Upon growth factor 
stimulation, the phosphorylated tyrosine residues of RTKs interact with SH2 domains of PLCγ and 
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Activated RTKs bind to the adaptive protein growth factor receptor-bound 2(Grb2) and recruit
Son of Sevenless homolog protein (SOS), which interacts with its downstream target Ras, a small
GTP binding protein, and transforms it to the active conformation by exchanging GDP for GTP [94].
Ras recruits the serine/threonine protein kinase, Raf, to the membrane, where it becomes activated
by phosphorylation. Once activated, Raf, a MAP3K, phosphorylates MAP2Ks, MEK1 and MEK2,
at specific serine residues, and activated MEK1/2 in turn catalyzes phosphorylation of ERK1/2 at
threonine and tyrosine residues [95]. Activated ERK1/2 phosphorylates many downstream target
proteins and transcription factors involved in cell function [32,96].
The phosphoinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling
pathway is also initiated by binding of growth factors to RTKs. Activated RTKs recruit the PI3K to the
plasma membrane where the PI3K subunit p110 catalyzes phosphorylation of phosphatidylinositol
4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3 then provides docking
sites for signaling proteins, including AKT and 3-phosphoinositide-dependent kinase 1 (PDK1) [97,98].
Activated AKT phosphorylates many other downstream proteins, such as glycogen synthase kinase
3 (GSK3), the forkhead family of transcription factors (FOXOs) and mTOR. Multiple components of
the PI3K/AKT/mTOR pathway activated by RKTs play a pivotal role in the regulation of cell growth,
proliferation and differentiation [93,98–100].
Another signaling system linked to RTKs is PLCγ/protein kinase C (PKC). Upon growth factor
stimulation, the phosphorylated tyrosine residues of RTKs interact with SH2 domains of PLCγ and lead
to its activation. PLCγ then hydrolyses PIP2 into two second messengers, inositol 1,4,5-trisphosphate
(IP3) and diacylglycerol (DAG). IP3 binds to its receptor on the endoplasmic reticulum (ER) surface,
whereas DAG mediates activation of PKC [101,102]. This process has a key role in regulating
intracellular Ca2+ through multiple Ca2+ channels [103–105]. PLCγ/PKC is also involved in the
regulation of cell proliferation, contraction and migration [106–108].
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The Janus kinase/signal transducer and activator of transcription (JAK/STAT) and the Src family
kinases (SFKs) are additional signaling pathways associated with RTK activation. Src family members,
including Src, Fyn and Yes, are recruited on RTKs, such as EGFR, FGFR and IGFR, and transmit
mitogenic signals to regulate DNA synthesis, cell survival, cell adhesion, motility and growth [32].
Once activated, STATs enter the nucleus and bind to specific regulatory sequences in target genes
regulating transcription [109].
4. Cross-Talk between TRPM6/7, Receptor Tyrosine Kinases and Signaling Kinases
4.1. Regulation of TRPM6/7 by Receptor Tyrosine Kinases
Upon ligand binding, VEGFR and EGFR undergo receptor dimerization and tyrosine
phosphorylation leading to recruitment of effector proteins and activation of downstream cascades.
These processes are highly regulated and are dependent on intracellular Mg2+. Increased RTK activation
and abnormal growth factor-mediated tyrosine kinase signaling is associated with uncontrolled cell
proliferation in cancer [110]. Accordingly, inhibitors of VEGFR and EGFR tyrosine kinases have
been used to treat several cancers. However unexpectedly these drugs have been associated with
unwanted secondary effects, including hypertension, cardiovascular and renal toxicity, and electrolyte
disorders [110–113].
One of the most significant electrolyte abnormalities associated with EGFR inhibitors in the
treatment of cancer is renal magnesium wasting and hypomagnesemia. In extreme cases, patients need
intravenous magnesium treatment and withdrawal of the EGFR inhibitor. This has major impact on
the effectiveness of cancer treatment [110–114]. Molecular mechanisms underlying these side effects
have been attributed to abnormal function of TRPM6, phenomena that were first described in patients
carrying a mutation in the EGF gene and who have severe hypomagnesemia and cognitive disability.
EGF binding to EGFR promotes TRPM6 translocation from cytosol to membrane in kidney cells [33].
This process was blocked by the EGFR monoclonal antibody, cetuximab [33,34]. Hence, EGF-EGFR
signaling involves TRPM6, which promotes Mg2+ transport into cells. Inhibition of these processes
with EGFR inhibitors decreases TRPM6 activity and reduces Mg2+ influx into cells, promoting Mg2+
excretion in the kidney with resultant Mg2+ wasting and hypomagnesemia.
Emerging evidence suggests that TRPM7 may also be regulated by growth factor signaling
through EGFR, as well as VEGFR [115–117]. Studies in transfected chinese hamster ovary (CHO)
cells showed inhibition of TRPM7 channel activity by EGF through mechanisms involving PLCγ and
PIP2 [117]. However, Gao et al. found that in pulmonary cancer cell lines, EGF, through its receptor,
enhanced the cell membrane protein expression and currents of TRPM7, a process associated with
cell migration [118]. The difference in models and cell lines may explain the conflicting data obtained
in these two studies. In hippocampal neurons, nerve growth factor (NGF) signals through receptor
tyrosine kinase TrkA, reducing the outward rectifying TRPM7-like current, effects blocked by inhibitors
of TrkA and PLC [119]. TrkA activation by NGF prevented upregulation of TRPM7 expression through
PI3K in hippocampal neurons subjected to ischemia-reperfusion and oxygen-glucose deprivation [120].
Moreover, PDGF stimulation was shown to increase TRPM7 expression in HSC-T6 hepatic stellate cells.
The non-specific TRPM7 inhibitor 2-aminoethyl diphenyl borinate (2-APB) diminished PDGF-mediated
activation of p-AKT and p-ERK, further suggesting a regulatory role for TRPM7 upstream of AKT and
ERK [121].
RTKs induce phosphorylation of downstream kinases that influence TRPM7 activity (Figure 6).
However these processes seem to be related to changes in the intracellular concentration of Mg2+,
because when [Mg2+]i is low, PLC activation is associated with TRPM7 inhibition, whereas in normal
[Mg2+]i conditions, activation of PLC increases TRPM7 currents [122]. In prostate cells, TRPM7
expression was mediated by Ca2+-dependent activation of ERK, since ERK inhibition reduced TRPM7
expression [123]. Ang II, which transactivates TKRs, increased TRPM7 expression through the AT1
receptor and ERK [124]. Bradykinin, another vasoactive peptide, regulates TPRM7 and its downstream
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target annexin-1 through PLC and c-Src dependent pathways, which have an important role in VSMC
Mg2+ homeostasis and cell migration and invasion [78]. The inflammatory mediator interleukin-18
(IL-18) activated TRPM7 currents and upregulated TRPM7 expression in an ERK1/2-dependent manner,
processes that influence osteogenic differentiation of VSMCs [125]. In HEK293 cells, interleukin-6
(IL-6) inhibited TRPM7 currents through JAK2-STAT3 signaling and appeared to be independent of
the TPRM7 α-kinase domain. Regulation of TRPM7 by IL-6 signaling may result from JAK2-STAT3
mediated phosphorylation of TRPM7 [126].Int. J. Mol. Sci. 2019, 20, x 9 of 19 
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4.2. Regulation of Signaling Kinases by TRPM7
While kinases regulate TRPM7, these kinases themselves may be targets of TRPM7. MAP kinases
are regulated by TRPM7. In human endothelial cells, downregulation of TRPM7 using a siRNA
approach was associated with increased ERK1/2 phosphorylation with no effects on p38MAPK or JNK
activation [127]. On the other hand, in HEK293 cells overexpressing TRPM7, ERK1/2 phosphorylation
was reduced, while phosphorylation of p38MAPK and JNK was increased [128]. In a rat hepatic stellate
cell line (HSC-T6), upregulation of TRPM7 promoted PDGF-induced activation of ERK1/2 and AKT
pathways [121]. In mouse cortical astrocytes and in rat VSMCs, TRPM7 siRNA was associated with
reduced ERK1/2 phosphorylation [129,130]. Additionally, TRPM7 siRNA reduced activation of Src,
p38 MAPK, ERK1/2 and JNK in a breast cancer cell line [131,132].
A regulatory role of TRPM7 in MAPK signaling has also been observed using pharmacological
approaches in cancer tissue and cell lines. In glioblastoma cells, naltriben, a pharmacological activator of
TRPM7 channel, enhanced ERK1/2 phosphorylation and proliferation, with no effect on the PI3K/AKT
pathway (150). Carvacrol, a non-specific inhibitor of TRPM7, suppressed phosphorylation of ERK1/2
and AKT, reducing cell proliferation [133–135]. Thus, there is accumulating evidence supporting a role
for TRPM7 in the regulation of MAPK signaling.
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The PI3K/AKT pathway is also affected by TRPM7. In mouse chondrocytes, overexpression of
TRPM7 stimulated the AKT pathway, while TRPM7 silencing inhibited AKT signaling [136]. In human
osteoblasts, Mg2+-induced increase in mRNA expression of chemotaxis-related genes was attenuated
by TRPM7 siRNA and PI3K inhibition, suggesting a link between TRPM7 and PI3K activation mediated
by Mg2+.
STAT3 is also modulated by TRPM7. TRPM7 siRNA reduced activation of STAT3 (Tyr705) by
affecting phosphorylation of the upstream protein JAK2, a non-receptor tyrosine kinase [137]. Reduced
TRPM7 expression was associated with inhibition of Notch activation (Notch1, JAG1, Hey2, and
Survivin), involved in angiogenesis and tumor growth mediated by VEGFR and EGFR [138,139].
In breast cancer cells, silencing TRPM7 reduced EGF-induced STAT3 activation and decreased
phosphorylation levels of Src, with reduced TRPM7-mediated migration and invasion [131,132].
5. TRPM7and Kinase Signaling—Pathophysiological Implications
TRPM7-regulated Mg2+ has versatile biological functions, contributing to all vital cellular processes,
including stability of tertiary structures of DNA and RNA, energy metabolism, enzyme activity,
signaling, cell cycle progression and cell differentiation [140,141]. The significance of TRPM7 in
development and cell viability was demonstrated in mice with global deletion of TRPM7. TRPM7
knockout mice are embryonic lethal and cardiac-targeted knockout of TRPM7 causes impaired
embryonic development of the heart [14,142]. The regulatory role of TRPM7 in cell differentiation has
been highlighted in various cell types. In mesenchymal stromal cells, TRPM7 mediates shear stress
and silencing TRPM7 accelerates osteogenic differentiation [143]. TRPM7 was also shown to mediate
differentiation in hepatic cells, lung fibroblasts, dental pulp stem cells and T cells [14,144–146]. Some of
these studies investigated underlying mechanisms of the involvement of TRPM7 in cell differentiation.
In addition to the contribution of Ca2+ and Mg2+, an interaction between TRPM7 and RTK downstream
effectors, including PI3K, AKT and ERK1/2, have been implicated [81,125,145,147–149].
Developmental experiments using zebrafish models of TRPM7 mutants showed abnormal pancreas
development, which was associated with increased expression of Suppressor of cytokine signaling
(SOCS)-3a, the zebrafish homologue to the human SOCS3, which is part of a classical negative feedback
system that influences cytokine signal transduction by reducing activation of JAK-STAT3. Mg2+
supplementation partially attenuated the phenotype [150]. Using genetic and pharmacologic inhibitors,
2-APB or TRPM7-siRNA, it was further shown that TRPM7 modulates effects of PDGF-BB on cell
proliferation by regulating activity of cell cycle proteins, including cyclin D1, PCNA and CDK4, through
mechanisms that involve tyrosine kinases, ERK1/2 and PI3K [121].
The effects of TRPM7 in pathologic cell differentiation has been intensively investigated in
cancer cells, including pancreas, ovary, breast and adenocarcinoma of lungs and prostate [118].
Expression of TRPM7 in these cancers was associated with increased expression of proliferative
markers. Epithelial-mesenchymal transition is involved in fibrosis and cancer metastasis and involves
EGF activation, effects attenuated by TRPM7 siRNA by mechanisms involving ERK1/2 and STAT3 [132].
Cancer stem cells are cells found within tumors and hematological cancers that have features of
normal stem cells, particularly the ability to self-renew and differentiate into multiple cell types [151].
They are rare immortal cells within tumors and are able to induce growth of new tumors and metastases.
They are found in numerous tumors and have been considered attractive targets for anti-cancer
therapy [152]. Many pathways have been implicated in the regulation of stem cell self-renewal and
oncogenesis, including signaling through Notch, Wnt and sonic hedgehog (Shh) [151,152]. In epithelial
tumors, epithelial-mesenchymal transition (EMT) seems to be important in cancer stem cell function.
Recent evidence indicates that cancer stem cell regulation involves TRPM7-dependent pathways.
In lung cancer cells, TRPM7 expression was increased and associated with enhanced SOX2, KLF4,
and CD133, Hsp90α, uPA, and MMP2 [153]. TRPM7-silencing inhibited epithelial-to-mesenchymal
transition (EMT), suppressed stemness markers and phenotypes, and attenuated activation of the
Hsp90α/uPA/MMP2 axis. These effects were ameliorated by waixenicin A, a bioactive extract of soft
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coral, which downregulated TRPM7 and oncogenic markers. Hence, waixenicin A was suggested as
an anticancer therapy, by inhibiting lung cancer stem cells through TRPM7 inhibition [153]. In glioma
tumorigenesis cancer stem cells, TRPM7 activates JAK2/STAT3- aldehyde dehydrogenase1 (ALDH1)
and Notch signaling pathways, contributing to the regulation of cell proliferation, migration and
invasion [137]. TRPM7 has also been implicated in epithelial-mesenchymal transition ovarian cancer
stem cells, through calcium-related PI3K/AKT oncogenic signaling [154]. In mesenchymal stromal
cells (MSCs), TRPM7 senses mechanical stimuli, such as intermittent fluid shear stress and membrane
tension, and regulates Ca2+ influx and phosphorylation of signaling kinases, Smad1/5 and p38
MAPK, whereas TRPM7 knockdown decreases MSC proliferation and viability, and induces cell
death [143]. Additionally, Mg2+ supplementation promoted osteogenic differentiation through the
activation of Notch signaling in MSCs, which was decreased by 2-APB [143,155–157]. In human dental
pulp stem cells, silencing TRPM7 inhibited proliferation, migration, and osteogenic differentiation,
supporting a role for TRPM7 in the dental pulp repair process [146]. Together, these studies suggest
that dysregulation of TRPM7 is important in cancer stem cell regulation and that TRPM7 may be a
therapeutic target for oncogenesis [158].
Interactions between RTKs, such as VEGFR and EGFR, TRPM6/7 and Mg2+, have also been
implicated in preeclampsia. In a study examining placentas from women with preeclampsia compared
to placentas from normotensive women, pre-eclamptic placentas had reduced expression of TRPM6 and
TRPM7 [159], which was linked to altered cellular Mg2+ homeostasis. These phenomena were associated
with decreased placental VEGF expression in preeclampsia versus normotensive pregnancies, effects
normalized by treatment with MgSO4 [160]. Together these findings suggest an important relationship
between VEGF, TRPM6/7 and Mg2+ in preeclampsia. This is clinically important because it provides a
mechanistic basis for the therapeutic use of MgSO4 as the drug of choice for preeclampsia [161].
6. Conclusions and Perspectives
TRPM7 and TRPM6 are unique proteins characterized by their channel and kinase domains, which
differentially regulate cell signaling and function. TRPM6 is mostly expressed in epithelial cells of the
kidney and gastrointestinal system, whereas TRPM7 is ubiquitously expressed. In the kidney, TRPM6
and cellular Mg2+ homeostasis are regulated by EGF signaling through EGFR. Inhibition of EGFR
signaling impairs TRPM6 function leading to renal Mg2+ wasting and consequent hypomagnesemia
in cancer patients treated with EGFR inhibitors [161]. It is still unclear if similar processes influence
TRPM7. Experimental studies, mainly in cell models, indicate that VEGFR and EGFR influence
TRPM7 activity and Ca2+ and Mg2+ mobilization. Changes in TRPM7 activity and altered Mg2+
homeostasis have a significant effect on tyrosine kinase signaling. Hence, RTKs influence TRPM7,
which in turn may influence tyrosine kinase signaling. Most studies have focused on EGFR signaling,
but growing evidence indicates that VEGFR and PDGFR also signal through TRPM7. The putative
cross-talk between TRPM7 and RTKs has clinical relevance, because inhibitors of RTKs, including
VEGFR and EGFR, are increasingly being used to treat cancer and inflammatory diseases. Hence,
knowing mechanisms whereby these drugs cause hypomagnesemia is important so that unwanted
side effects can be managed in a mechanism-specific manner. The field of TRPM6/7 and RTKs is still
immature and further studies are required to unravel the complex interplay between these systems.
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